Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections
Status:
Not yet recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
Cutibacterium acnes is involved in nearly 40% of shoulder prosthetic joint infections (PJI).
After shoulder prothesis, C. acnes mainly affects hip prosthesis. One recent work from the
Lyon (France) bone and joint infections reference center with data focusing mainly on hip and
knee PJI has reported that C. acnes is the leading cause of late-onset PJI after coagulase
negative staphylococci (CNS) (late acute PJI not considered).
In such late-onset device-related infection, biofilm, as produced by C. acnes during PJI
represents a major hurdle on the path to patient's cure. Because biofilm-associated bacteria
have a slower metabolism and a lower multiplication rate than planktonic bacteria, antibiotic
susceptibility can be hampered.
Rifampicin is an antibiotic with low minimal bactericidal concentration against S. aureus and
CNS biofilm-associated bacteria8 which significantly influence patient's outcome during
staphylococci PJI.
Phase:
Phase 3
Details
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Treatments:
Amoxicillin Moxifloxacin Norgestimate, ethinyl estradiol drug combination Rifampin